{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:00:50Z","timestamp":1792119650678,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/ncomms4401","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T12:57:20Z","timestamp":1393419440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":176,"title":["Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma"],"prefix":"10.1038","volume":"5","author":[{"given":"Barbara","family":"Heidenreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Nagore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Sivaramakrishna","family":"Rachakonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaida","family":"Garcia-Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Traves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadem","family":"Soufir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"key":"BFncomms4401_CR1","doi-asserted-by":"crossref","unstructured":"Eggermont, A. M., Spatz, A. & Robert, C. Cutaneous melanoma. Lancet doi:10.1016\/S0140-6736(13)60802-8 (2013).","DOI":"10.1016\/S0140-6736(13)60802-8"},{"key":"BFncomms4401_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/pcmr.12172","volume":"27","author":"RR Braeuer","year":"2013","unstructured":"Braeuer, R. R. et al. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 27, 19\u201336 (2013).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFncomms4401_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"BFncomms4401_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263 (2012).","journal-title":"Cell"},{"key":"BFncomms4401_CR5","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","volume":"19","author":"VJ Mar","year":"2013","unstructured":"Mar, V. J. et al. BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin. Cancer Res. 19, 4589\u20134598 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms4401_CR6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.2359","volume":"44","author":"M Krauthammer","year":"2012","unstructured":"Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006\u20131014 (2012).","journal-title":"Nat. Genet."},{"key":"BFncomms4401_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/ng.810","volume":"43","author":"X Wei","year":"2011","unstructured":"Wei, X. et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442\u2013446 (2011).","journal-title":"Nat. Genet."},{"key":"BFncomms4401_CR8","doi-asserted-by":"publisher","first-page":"13481","DOI":"10.1073\/pnas.1304227110","volume":"110","author":"JJ Gartner","year":"2013","unstructured":"Gartner, J. J. et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc. Natl Acad. Sci. USA 110, 13481\u201313486 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms4401_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959\u2013961 (2013).","journal-title":"Science"},{"key":"BFncomms4401_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957\u2013959 (2013).","journal-title":"Science"},{"key":"BFncomms4401_CR11","doi-asserted-by":"publisher","first-page":"17426","DOI":"10.1073\/pnas.1310522110","volume":"110","author":"PS Rachakonda","year":"2013","unstructured":"Rachakonda, P. S. et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl Acad. Sci. USA 110, 17426\u201317431 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms4401_CR12","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021\u20136026 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms4401_CR13","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/ncomms3185","volume":"4","author":"J Vinagre","year":"2013","unstructured":"Vinagre, J. et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013).","journal-title":"Nat. Commun."},{"key":"BFncomms4401_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00401-013-1203-9","volume":"126","author":"H Arita","year":"2013","unstructured":"Arita, H. et al. TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol. 126, 939\u2013941 (2013).","journal-title":"Acta Neuropathol."},{"key":"BFncomms4401_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.gde.2013.11.005","volume":"24","author":"B Heidenreich","year":"2014","unstructured":"Heidenreich, B., Rachakonda, P. S., Hemminki, K. & Kumar, R. TERT promoter mutations in cancer development. Curr. Opin. Genet. Dev. 24, 30\u201337 (2014).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFncomms4401_CR16","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/ncomms3218","volume":"4","author":"JC Nault","year":"2013","unstructured":"Nault, J. C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 2218 (2013).","journal-title":"Nat. Commun."},{"key":"BFncomms4401_CR17","doi-asserted-by":"crossref","unstructured":"Tallet, A. et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene doi:10.1038\/onc.2013.351 (2013).","DOI":"10.1038\/onc.2013.351"},{"key":"BFncomms4401_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-013-1141-6","volume":"126","author":"H Arita","year":"2013","unstructured":"Arita, H. et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 126, 267\u2013276 (2013).","journal-title":"Acta Neuropathol."},{"key":"BFncomms4401_CR19","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1158\/1538-7445.CEC13-IA04","volume":"73","author":"N Papadopoulos","year":"2013","unstructured":"Papadopoulos, N. et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 73, 7162\u20137167 (2013).","journal-title":"Cancer Res."},{"key":"BFncomms4401_CR20","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","volume":"98","author":"I Landa","year":"2013","unstructured":"Landa, I. et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J. Clin. Endocrinol. Metab. 98, E1562\u2013E1566 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFncomms4401_CR21","doi-asserted-by":"crossref","unstructured":"Liu, T. et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene doi:10.1038\/onc.2013.446 (2013).","DOI":"10.1038\/onc.2013.446"},{"key":"BFncomms4401_CR22","doi-asserted-by":"publisher","first-page":"D102","DOI":"10.1093\/nar\/gkm955","volume":"36","author":"JC Bryne","year":"2008","unstructured":"Bryne, J. C. et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res. 36, (Database issue): D102\u2013D106 (2008).","journal-title":"Nucleic Acids Res."},{"key":"BFncomms4401_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0092-8674(03)00550-6","volume":"114","author":"K Masutomi","year":"2003","unstructured":"Masutomi, K. et al. Telomerase maintains telomere structure in normal human cells. Cell 114, 241\u2013253 (2003).","journal-title":"Cell"},{"key":"BFncomms4401_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.gde.2010.01.005","volume":"20","author":"RM Marion","year":"2010","unstructured":"Marion, R. M. & Blasco, M.A. Telomere rejuvenation during nuclear reprogramming. Curr. Opin. Genet. Dev. 20, 190\u2013196 (2010).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFncomms4401_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tibs.2013.07.001","volume":"38","author":"KC Low","year":"2013","unstructured":"Low, K. C. & Tergaonkar, V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem. Sci. 38, 426\u2013434 (2013).","journal-title":"Trends Biochem. Sci."},{"key":"BFncomms4401_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/hmg\/10.7.677","volume":"10","author":"JW Shay","year":"2001","unstructured":"Shay, J. W., Zou, Y., Hiyama, E. & Wright, W. E. Telomerase and cancer. Hum. Mol. Genet. 10, 677\u2013685 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"BFncomms4401_CR27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00401-013-1195-5","volume":"126","author":"C Koelsche","year":"2013","unstructured":"Koelsche, C. et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 126, 907\u2013915 (2013).","journal-title":"Acta Neuropathol."},{"key":"BFncomms4401_CR28","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970\u2013976 (2013).","journal-title":"Nat. Genet."},{"key":"BFncomms4401_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","volume":"65","author":"Y Allory","year":"2013","unstructured":"Allory, Y. et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur. Urol. 65, 360\u2013366 (2013).","journal-title":"Eur. Urol."},{"key":"BFncomms4401_CR30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.eururo.2013.08.057","volume":"65","author":"CD Hurst","year":"2013","unstructured":"Hurst, C. D., Platt, F. M. & Knowles, M. A. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur. Urol. 65, 367\u2013369 (2013).","journal-title":"Eur. Urol."},{"key":"BFncomms4401_CR31","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/jnci\/djg123","volume":"95","author":"JL Maldonado","year":"2003","unstructured":"Maldonado, J. L. et al. Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst. 95, 1878\u20131890 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"BFncomms4401_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","volume":"24","author":"J Bauer","year":"2011","unstructured":"Bauer, J. et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 24, 345\u2013351 (2011).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFncomms4401_CR33","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/1346-8138.12165","volume":"40","author":"T Watanabe","year":"2013","unstructured":"Watanabe, T. et al. Novel morphological study of solar lentigines by immunohistochemical and electron microscopic evaluation. J. Dermatol. 40, 528\u2013532 (2013).","journal-title":"J. Dermatol."},{"key":"BFncomms4401_CR34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","volume":"164","author":"JH Lee","year":"2011","unstructured":"Lee, J. H., Choi, J. W. & Kim, Y. S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 164, 776\u2013784 (2011).","journal-title":"Br. J. Dermatol."},{"key":"BFncomms4401_CR35","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/SLA.0b013e31824c4b0b","volume":"255","author":"FE In 't Hout","year":"2012","unstructured":"In 't Hout, F. E. et al. Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. Ann. Surg. 255, 1165\u20131170 (2012).","journal-title":"Ann. Surg."},{"key":"BFncomms4401_CR36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.amjsurg.2013.09.003","volume":"206","author":"ME Egger","year":"2013","unstructured":"Egger, M. E. et al. Outcomes and prognostic factors in superficial spreading melanoma. Am. J. Surg. 206, 861\u2013868 (2013).","journal-title":"Am. J. Surg."},{"key":"BFncomms4401_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CMR.0b013e32834e6aa0","volume":"22","author":"HS Greenwald","year":"2012","unstructured":"Greenwald, H. S., Friedman, E. B. & Osman, I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res. 22, 1\u20138 (2012).","journal-title":"Melanoma Res."},{"key":"BFncomms4401_CR38","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1002\/cncr.23955","volume":"113","author":"MA Warycha","year":"2008","unstructured":"Warycha, M. A. et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 113, 3341\u20133348 (2008).","journal-title":"Cancer"},{"key":"BFncomms4401_CR39","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2012.01.039","volume":"148","author":"Z Ding","year":"2012","unstructured":"Ding, Z. et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148, 896\u2013907 (2012).","journal-title":"Cell"},{"key":"BFncomms4401_CR40","doi-asserted-by":"publisher","first-page":"11306","DOI":"10.1073\/pnas.0510085103","volume":"103","author":"S Bagheri","year":"2006","unstructured":"Bagheri, S. et al. Genes and pathways downstream of telomerase in melanoma metastasis. Proc. Natl Acad. Sci. USA 103, 11306\u201311311 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms4401_CR41","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1046\/j.0022-202X.2004.22225.x","volume":"122","author":"R Kumar","year":"2004","unstructured":"Kumar, R., Angelini, S., Snellman, E. & Hemminki, K. BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol. 122, 342\u2013348 (2004).","journal-title":"J. Invest. Dermatol."},{"key":"BFncomms4401_CR42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/sj.onc.1210704","volume":"27","author":"C Michaloglou","year":"2008","unstructured":"Michaloglou, C., Vredeveld, L. C. & Mooi, W. J. Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene 27, 877\u2013895 (2008).","journal-title":"Oncogene"},{"key":"BFncomms4401_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.trsl.2013.08.009","volume":"162","author":"PJ Mason","year":"2013","unstructured":"Mason, P. J. & Perdigones, N. Telomere biology and translational research. Transl. Res. 162, 333\u2013342 (2013).","journal-title":"Transl. Res."},{"key":"BFncomms4401_CR44","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ctrv.2012.06.007","volume":"39","author":"M Ruden","year":"2013","unstructured":"Ruden, M. & Puri, N. Novel anticancer therapeutics targeting telomerase. Cancer Treat. Rev. 39, 444\u2013456 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"BFncomms4401_CR45","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","volume":"49","author":"RJ Sullivan","year":"2013","unstructured":"Sullivan, R. J. & Flaherty, K. T. Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 49, 1297\u20131304 (2013).","journal-title":"Eur. J. Cancer"},{"key":"BFncomms4401_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0001-7310(09)70536-8","volume":"100","author":"E Nagore","year":"2009","unstructured":"Nagore, E. et al. Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site. Actas Dermosifiliogr. 100, 205\u2013211 (2009).","journal-title":"Actas Dermosifiliogr."},{"key":"BFncomms4401_CR47","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1001\/archderm.1990.01670300070010","volume":"126","author":"RP Gallagher","year":"1990","unstructured":"Gallagher, R. P. et al. Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Similarities to melanoma: the Vancouver Mole Study. Arch. Dermatol. 126, 770\u2013776 (1990).","journal-title":"Arch. Dermatol."},{"key":"BFncomms4401_CR48","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/ijc.24548","volume":"125","author":"D Scherer","year":"2009","unstructured":"Scherer, D. et al. Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations. Int. J. Cancer 125, 1868\u20131875 (2009).","journal-title":"Int. J. Cancer"},{"key":"BFncomms4401_CR49","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/jid.2012.385","volume":"133","author":"E Hacker","year":"2013","unstructured":"Hacker, E. et al. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. J. Invest. Dermatol. 133, 1027\u20131033 (2013).","journal-title":"J. Invest. Dermatol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms4401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms4401","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms4401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T03:50:09Z","timestamp":1672977009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms4401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,5,20]]}},"alternative-id":["BFncomms4401"],"URL":"https:\/\/doi.org\/10.1038\/ncomms4401","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,26]]},"assertion":[{"value":"13 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3401"}}